Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis

Institution:	1. Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands;2. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Room E.01.1.29, Internal Mail E01.132, P.O. 85500, 3508 GA Utrecht, The Netherlands;3. Departments of Surgery, University Medical Center Utrecht, Room E.01.1.29, Internal Mail E01.132, P.O. 85500, 3508 GA Utrecht, The Netherlands;4. Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland;5. Department of Interventional Radiology, Vanderbilt University Medical Center, Nashville, Tennessee;6. Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas;7. Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas;8. Department of Medical Oncology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom;9. Department of Radiology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom;10. Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom;11. Department of Interventional Radiology, Stanford University Medical Center, Stanford, California;1. Department of Chemistry, Sapienza University, Rome, Italy;2. Department of Basic and Applied Sciences for Engineering, Sapienza University, Rome, Italy;3. Department of Physics, Sapienza University, Rome, Italy;4. INFN, sezione di Roma, Rome, Italy;5. Institute of Nucleare Medicine, Università Cattolica del Sacro Cuore, Rome, Italy;6. Department of Chemistry and Technologies of Drugs, Sapienza University, Rome, Italy;7. National Center for Innovative Technologies in Public Health, Istituto Superiore di Sanità – National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy;8. Università Cattolica del Sacro Cuore, Rome, Istituto di Biochimica e Biochimica Clinica, Rome, Italy;1. Department of Radiology, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 556, Little Rock, AR 72205;2. Department of Biostatistics, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 556, Little Rock, AR 72205;3. Department of Surgery, Surgical Oncology and Transplant Surgery, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 556, Little Rock, AR 72205;1. Division of Interventional Radiology, Department of Radiology, University of Illinois Health, Chicago, Illinois;2. Department of Pathology, University of Illinois Health, Chicago, Illinois;3. Center for Clinical and Translational Science, University of Illinois at Chicago, Chicago, Illinois;4. Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, M-361, San Francisco, CA 94143;1. Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina;2. Rush University Medical Center, Chicago, Illinois;3. Georgetown University Hospital, Washington, District of Columbia, American College of Surgeons;4. Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland, American Society of Clinical Oncology;5. Interventional Endoscopy and Pancreatic Diseases, New Haven, Connecticut, American Gastroenterological Association;6. University of Illinois Hospital, Chicago, Illinois;7. Massachusetts General Hospital, Boston, Massachusetts;8. University of Colorado, Anschutz Medical Campus, Aurora, Colorado;9. Oregon Health and Science University, Portland, Oregon;10. Riley Hospital for Children, Indianapolis, Indiana;11. University of Wisconsin, Madison, Wisconsin;12. Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois;13. University of Illinois Hospital and Health Science System, Chicago, Illinois;14. Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin;1. Department of Interventional Radiology, Clínica Universidad de Navarra, Avenida Pio XII, no. 36, Pamplona 31008, Spain;2. Department of Nuclear Medicine, Clínica Universidad de Navarra, Avenida Pio XII, no. 36, Pamplona 31008, Spain;3. Department of Oncology, Clínica Universidad de Navarra, Avenida Pio XII, no. 36, Pamplona 31008, Spain;4. Department of Radiology, Clínica Universidad de Navarra, Avenida Pio XII, no. 36, Pamplona 31008, Spain;5. Liver Unit, Clínica Universidad de Navarra, Avenida Pio XII, no. 36, Pamplona 31008, Spain

Abstract:	PurposeTo report outcomes of yttrium-90 (⁹⁰Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC).Materials and MethodsRetrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with χ² tests. Survival after diagnosis and after treatment was assessed by Kaplan–Meier method.ResultsGrade 3 laboratory toxicity was observed in 4 patients (4%); no difference in toxicity profile between resin and glass microspheres was observed (P = .350). Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%). Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008). Median overall survival (OS) from first diagnosis was 29 months (95% confidence interval CI], 21–37 mo) for all patients, and 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8–13 mo), and 1- and 3-year OS rates were 44% and 4%, respectively. These estimates were not significantly different between resin and glass microspheres (P = .730 and P = .475, respectively). Five patients were able to undergo curative-intent resection after ⁹⁰Y radioembolization (4%).ConclusionsThis study provides observational data of treatment outcomes after ⁹⁰Y radioembolization in patients with unresectable ICC.

Keywords:	CI"} {"#name":"keyword" "$":{"id":"kwrd0015"} "$$":[{"#name":"text" "_":"confidence interval 5-FU"} {"#name":"keyword" "$":{"id":"kwrd0025"} "$$":[{"#name":"text" "_":"5-fluorouracil HAI"} {"#name":"keyword" "$":{"id":"kwrd0035"} "$$":[{"#name":"text" "_":"hepatic arterial infusion ICC"} {"#name":"keyword" "$":{"id":"kwrd0045"} "$$":[{"#name":"text" "_":"intrahepatic cholangiocarcinoma IQR"} {"#name":"keyword" "$":{"id":"kwrd0055"} "$$":[{"#name":"text" "_":"interquartile range MISPHEC"} {"#name":"keyword" "$":{"id":"kwrd0065"} "$$":[{"#name":"text" "_":"Microspheres in Cholangiocarcinoma [trial] OR"} {"#name":"keyword" "$":{"id":"kwrd0075"} "$$":[{"#name":"text" "_":"overall survival PFS"} {"#name":"keyword" "$":{"id":"kwrd0085"} "$$":[{"#name":"text" "_":"progression-free survival RECIST"} {"#name":"keyword" "$":{"id":"kwrd0095"} "$$":[{"#name":"text" "_":"Response Evaluation Criteria In Solid Tumors REILD"} {"#name":"keyword" "$":{"id":"kwrd0105"} "$$":[{"#name":"text" "_":"radioembolization-induced liver disease
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏